Related Experiment Videos
[Effect of aprotinin in acute myocardial infarction (clinical double-bind study (author's transl)]
Insights
Aprotinin (Trasylol) showed no therapeutic benefit for acute myocardial infarction patients in a randomized trial. The drug did not influence infarction progression, hemodynamics, arrhythmias, or mortality rates.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Identifying effective treatments to improve outcomes in AMI is crucial.
Purpose of the Study:
- To evaluate the efficacy of aprotinin (Trasylol) in patients with acute myocardial infarction.
Main Methods:
- A double-blind, randomized study involving 164 AMI patients admitted to intensive care within 72 hours.
- Patients received either aprotinin (Trasylol) or placebo for three days.
Main Results:
- No significant difference was observed in the course of infarction between the aprotinin and placebo groups.
- Aprotinin did not demonstrate a definite influence on hemodynamic changes, arrhythmias, or mortality rates.
Conclusions:
- Aprotinin (Trasylol) has no demonstrated therapeutic importance in the management of acute myocardial infarction.
- Further research may be needed to explore other therapeutic avenues for AMI.
Abstract:
In a double-bind study 164 patients with acute myocardial infarction, admitted to an intensive-care unit within 72 hours of infarction, were randomly treated for three days either with aprotinin (Trasylol-82 persons) or placebo (82 persons). Retrospective analysis proved both patient groups to have been comparable in all other respects. There was no definite influence on the course of the infarction, haemodynamic changes, arrythmias or mortality rate. Trasylol thus has no therapeutic importance in the treatment of acute myocardial infarction.